Pfizer Canada Inc.
Call for patient/clinician input open:
Call for patient/clinician input closed:
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.